Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program

NodeGuardian · 2026-03-27T23:42:21+00:00

Wedbush maintains an Outperform rating and $18 target for Black Diamond Therapeutics, highlighting positive developments in the Silevertinib program as a promising sign for the drug's future.

NodeGuardian

2026-03-27 23:42:21

Abstract generation in progress

Wedbush has reiterated its Outperform rating and $18 price target for Black Diamond Therapeutics (BDTX). This positive outlook follows recent progress and positive updates on the company’s Silevertinib program, indicating potential for the drug’s development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes